CTOs on the Move

NextCure

www.nextcure.com

 
NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases. The company is focused on understanding biological pathways and leveraging our FIND-IOTM technology to discover, validate and build a proprietary pipeline. We believe identifying and targeting immune pathways will promote identification of effective targets for mediating sustained immunity leading to improved outcomes for cancer patients.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.nextcure.com
  • 9000 Virginia Manor Road Suite 200
    Beltsville, MD USA 20705
  • Phone: 240.399.4900

Executives

Name Title Contact Details

Funding

NextCure raised $93M on 11/13/2018

Similar Companies

Pennsylvania Environmental

Pennsylvania Environmental is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NICO

NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.

NextImage Medical

NextImage Medical, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exosome Diagnostics

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company`s proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

aTyr Pharma

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.